Vincent PIRAS, PhD
Group Leader Oncology Bioinformatics / Principal Scientist
Evotec SE
Group Leader Oncology Bioinformatics / Principal Scientist
Evotec SE
I am a computational biologist with a software engineering background, with a 20+ years experience in bioinformatics, specialized in developing approaches for multi-omics biological data analysis, in oncology and other diseases,, with a focus on large patient cohorts, high throughput versatile datasets, biological relationships mining, and the development of integrated pipelines and applications for drug discovery projects, including AI and predictive models for patient response and drug mechanism of action.
Barlier C, Simplicien M, Hermoso A, Pourrat A, Moreau E, Fontana C, Delherme A, Daluege N, Bharaj G, de Oliveira C, Vogt A, Piras V, Hoareau-Aveilla C, Boulay G, Paiva I (2026) The impact of fulvestrant on estrogen receptor-driven chromatin dynamics in breast cancer cells. Epigenetics & Chromatin https://doi.org/10.1186/s13072-026-00667-0
[Full text] [PDF] [PMID:41840649]
Chang L-H, Ghosh S, Papale A, Luppino JM, Miranda M, Piras V, Degrouard J, Edouard J, Poncelet M, Lecouvreur N, Bloyer S, Leforestier A, Joyce EF, Holcman D, Noordermeer D S (2023) Multi-feature clustering of CTCF binding creates robustness for loop extrusion blocking and Topologically Associating Domain boundaries. Nature Communications 14:5615
[Full text] [PDF] [PMID:37699887]
Maser IP, Lacher S, Piras V, Kracher B, Zanziger K, Yule M, Loferer H, Bissinger S. (2023)
Development of a predictive biomarker signature for the highly potent SIK3 inhibitor OMX-0407.
In: Proceedings of the AACR Annual Meeting 2023, 2023:953.
[Abstract] [PDF]
Paillasse M, Garner J, Fitzgerald M, Friend J, Davenne L, Ancey PB, Poussereau-Pomie C, Esquerre M, Badet G, Yuyaret J, Bozec T, Piras V, Mandron M, Rochaix P, Ayyoub M, Scarlata CM, Caux C, Caux C, Cassier C, Gomez Roca C, Delord JP, Fons P. (2022)
Cutting edge biomarkers strategy to provide early insights into activity of EVT801, a novel selective VEGFR-3 inhibitor that targets tumor angiogenesis during the FIH clinical trial.
In: Proceedings of the AACR Annual Meeting 2022, 2022:3203.
[Abstract]
Kychygina A, Dall’Osto M, Allen JAM, Cadoret JC, Piras V, Pickett HA, Crabbe L* (2021)
Progerin impairs 3D genome organization and induces fragile telomeres by limiting the dNTP pools.
Scientific Reports, 11:13195
[Full text] [PDF] [PMID:34162976]